Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for ELIQUIS
- DOAC in Patients With Child B Liver Cirrhosis
- A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants
- Apixaban Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal Disconnection
- Apixaban in Patients With Left Ventricular Thrombus
- A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
- Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis
- Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome
- COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis
- Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）
- COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation
- A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome
- Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients
- Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy
- Clopidogrel Aspirin Therapy (CAT) Versus Apixiban Aspirin Therapy (AAT) After Lower Limb Revascularization
- Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism
- Drug Interaction Study of Apixaban With Cyclosporine or Tacrolimus in Transplant Recipients
- DOAC Versus VKA After Cardiac Surgery
- PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation
- Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism
- Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis
- MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention
- Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
- Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation
- Calf Deep Vein Thrombosis Treatment Trial
- Bioavailability of Apixaban Sprinkle Compared to Apixaban Capsules
- Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy
- Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study
- A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
- Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
- Apixaban Versus Warfarin in Patients With Left Ventricular (LV) Thrombus
- Apixaban For Thromboprophylaxis In Patients With Acute Spinal Cord Injury
- AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
- Start or STop Anticoagulants Randomised Trial (SoSTART)
- A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
- Evolution of Coagulation Activity in Non Valvular Atrial Fibrillation Patients Under Apixaban
- Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus
- Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
- Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus
- A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation
- Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis
- Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
- Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)
- Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation
- ELIQUIS (APIXABAN) Regulatory Post-Marketing Surveillance In Clinical Practice for Venous Thromboembolism (VTE) Treatment and Prevention Of Recurrent VTE
- RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding
- A Pilot Study Investigating Apixaban and Dexamethasone InterAction in Multiple Myeloma
- Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
- DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation
- Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation
- Pharmacokinetics of Apixaban in Nephrotic Syndrome
- Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
- Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP Study
- Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation
- Comparison of Bleeding Risk Between Rivaroxaban and Apixaban
- Apixaban in Patients Who Undergo CIED Procedure- Randomized Pilot Study
- Apixaban for Treatment of Embolic Stroke of Undetermined Source
- Apixaban Pharmacokinetics in Bariatric Patients (APB)
- Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli
- Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy
- Early Post-Marketing Study of ELIQUIS (Apixaban) in Mexico
- Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome
- Early Post-marketing Study of Eliquis (Apixaban)
- Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque
- Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients
- Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation
- Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation
- Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events
- Eliquis Regulatory Post Marketing Surveillance
- Eliquis Regulatory Post Marketing Surveillance (rPMS)
- Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)
- Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery
- Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events
Clinical trials list
click for details